Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023年8月15日 - 7:02AM
ビジネスワイヤ(英語)
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing CompanyTM, today announced
that the Compensation Committee of Quantum-Si’s Board of Directors
has granted non-qualified stock option awards to purchase an
aggregate of 739,750 shares of its Class A common stock to 8 new
employees under the Company’s previously adopted Quantum-Si
Incorporated 2023 Inducement Equity Incentive Plan (the “2023
Inducement Plan”). The stock options were granted as inducements
material to the new employees becoming employees of Quantum-Si in
accordance with Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Quantum-Si (or following a bona fide period of non-employment), as
an inducement material to such individuals’ entering into
employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
The options have an exercise price of $3.24 per share, which is
equal to the closing price of Quantum-Si’s Class A common stock on
The Nasdaq Global Market on July 17, 2023, the date of grant of the
options. Each option will vest over a four-year period, with 25% of
the shares vesting on the last day of the calendar quarter that is
12 months after the employee’s start date and the remaining shares
vesting monthly over the following 36-months, subject to each
employee’s continued employment with Quantum-Si on such vesting
dates. The options are subject to the terms and conditions of the
2023 Inducement Plan and the terms and conditions of a stock option
agreement covering the grant.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
www.quantum-si.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230814453026/en/
Investor Contact Juan Avendano ir@quantum-si.com
Media Contact Michael Sullivan media@quantum-si.com
Quantum Si (NASDAQ:QSI)
過去 株価チャート
から 5 2024 まで 6 2024
Quantum Si (NASDAQ:QSI)
過去 株価チャート
から 6 2023 まで 6 2024